Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections

References

• Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet365(9461), 785–799 (2005).
   PubMed Web of Science ®Google Scholar
• Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension41(3), 437–445 (2003).
   PubMed Web of Science ®Google Scholar
• Irgens HU, Reisater L, Irgens LM, Lie RT, Roberts JM. Long term mortality of mothers and fathers after preeclampsia: population based cohort study Preeclampsia and cardiovascular disease later in life: who is at risk? BMJ323(7323), 1213–1217 (2001).
   PubMed Web of Science ®Google Scholar
• Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med.359(8), 800–809 (2008).
   PubMed Web of Science ®Google Scholar
• Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA285(12), 1607–1612 (2001).
   PubMed Web of Science ®Google Scholar
• Hubel CA, Snaedal S, Ness RB et al. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG107(6), 776–784 (2000).
   PubMedGoogle Scholar
• Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG112(11), 1486–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ335(7627), 974 (2007).
   PubMed Web of Science ®Google Scholar
• Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA294(21), 2751–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Linke A, Li W, Huang H, Wang Z, Hintze TH. Role of cardiac eNOS expression during pregnancy in the coupling of myocardial oxygen consumption to cardiac work. Am. J. Physiol. Heart Circ. Physiol.283(3), H1208–H1214 (2002).
   Google Scholar
• Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol.294(2), H541–H550 (2008).
   PubMed Web of Science ®Google Scholar
• Bosio P, Mckenna P, Conroy R, O’Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet. Gynecol.94(6), 978–984 (1999).
   PubMed Web of Science ®Google Scholar
• Israel A, Peceno A. Renin–angiotensin–aldosterone system in pregnancy-induced hypertension. J. Hum. Hypertens.14(Suppl. 1), S36–S39 (2000).
   PubMed Web of Science ®Google Scholar
• Blanco MV, Roisinblit J, Grosso O et al. Left ventricular function impairment in pregnancy-induced hypertension. Am. J. Hypertens.14(3), 271–275 (2001).
   PubMedGoogle Scholar
• Borghi C, Esposti DD, Immordino V et al. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am. J. Obstet. Gynecol.183(1), 140–147 (2000).
   PubMed Web of Science ®Google Scholar
• Nishimura MD, Tajik MD. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta stone. J. Am. Coll. Cardiol.30(1), 8–18 (1997).
   PubMed Web of Science ®Google Scholar
• Yuan L, Duan Y, Cao T. Echocardiographic study of cardiac morphological and functional changes before and after parturition in pregnancy-induced hypertension. Echocardiography23(3), 177–182 (2006).
   PubMedGoogle Scholar
• Kuwahara F, Kai H, Tokuda K et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension43(4), 739–745 (2004).
   PubMed Web of Science ®Google Scholar
• Craici I, Wagner S, Garovic VD. Review: preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther. Adv. Cardiovasc. Dis.2(4), 249–259 (2008).
   PubMedGoogle Scholar
• Freeman DJ, McManus F, Brown EA et al. Short-and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension44(5), 708–714 (2004).
   PubMed Web of Science ®Google Scholar
• Hubel CA, Wallukat G, Wolf M et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension49(3), 612–617 (2007).
   PubMed Web of Science ®Google Scholar
• Hubel CA, Powers RW, Snaedal S et al. C-reactive protein is elevated 30 years after eclamptic pregnancy. Hypertension51(6), 1499–1505 (2008).
   PubMed Web of Science ®Google Scholar
• Alexander BT. Placental insufficiency leads to development of hypertension in growth-restricted offspring. Hypertension41(3), 457–462 (2003).
   PubMed Web of Science ®Google Scholar
• Alexander BT, Hendon AE, Ferril G, Dwyer TM. Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion. Hypertension45(4), 754–758 (2005).
   PubMed Web of Science ®Google Scholar
• Lu F, Bytautiene E, Tamayo E et al. Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. Am. J. Obstet. Gynecol.197(4), 418–415 (2007).
   PubMedGoogle Scholar
• Lu F, Longo M, Tamayo E et al. The effect of overexpression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol.196(4), 396–396 (2007).
   PubMedGoogle Scholar
• Gilbert JS, Knoblich PR, Steck S. Effects of regular, voluntary gestational exercise on the development of hypertension in offspring. FASEB J.16(5), A1141–A1141 (2002).
   PubMedGoogle Scholar
• Fisher SJ, Roberts JM. Defects in placentation and placental perfusion. In: Chelsey’s Hypertensive Disorders in Pregnancy. Lindheimer MD, Roberts JM, Cunningham FG (Eds). Appleton & Lange, Stanford, CT, USA (1999).
   Google Scholar
• Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am. J. Reprod. Immunol37(3), 240–249 (1997).
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J et al. Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.111(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Makris A, Thornton C, Thompson J et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int.71(10), 977–984 (2007).
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension50, 1142–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med.12(6), 642–649 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf M, Shah A, Lam C et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am. J. Obstet. Gynecol.193(1), 16–22 (2005).
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab.89(2), 770–775 (2004).
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab.90(8), 4895–4903 (2005).
   PubMed Web of Science ®Google Scholar
• Rajakumar A, Michael HM, Rajakumar PA et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta26(7), 563–573 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med.350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med.355(10), 992–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension46(5), 1077–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int.67(6), 2101–2113 (2005).
   PubMed Web of Science ®Google Scholar
• Tranquilli AL, Bezzeccheri V, Giannubilo SR, Scagnoli C, Mazzanti L, Garzetti GG. Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol.113(1), 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension50(1), 137–142 (2007).
   PubMed Web of Science ®Google Scholar
• Nevo O, Soleymanlou N, Wu Y et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am. J. Physiol. Regul. Integr. Comp. Physiol.291(4), R1085–R1093 (2006).
   PubMed Web of Science ®Google Scholar
• Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the ‘chicken-and-egg’ question. Endocrinology145(11), 4835–4837 (2004).
   PubMed Web of Science ®Google Scholar
• Ianosi-Irimie M, Vu HV, Whitbred JM et al. A rat model of preeclampsia. Clin. Exp. Hypertens.27(8), 605–617 (2005).
   PubMed Web of Science ®Google Scholar
• Dokras A, Hoffmann DS, Eastvold JS et al. Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia. Biol. Reprod.75(6), 899–907 (2006).
   PubMed Web of Science ®Google Scholar
• Davisson RL, Hoffmann DS, Butz GM et al. Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension39(2 Pt 2), 337–342 (2002).
   PubMed Web of Science ®Google Scholar
• Kanasaki K, Palmsten K, Sugimoto H et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature453(7198), 1117–1121 (2008).
   PubMed Web of Science ®Google Scholar
• Sedeek M, Gilbert JS, LaMarca BB et al. Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. Am. J. Hypertens.21(10), 1152–1156 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat. Med.14(8), 855–862 (2008).
   PubMed Web of Science ®Google Scholar
• Colson D, Gilbert JS, Bridges J et al. Oxidative stress mediates soluble Flt-1 induced vascular dysfunction in pregnant rats. FASEB J.22(Meeting abstracts), 969.7 (2008).
   Google Scholar
• Bridges JP, Gilbert JS, Colson D et al. Soluble Flt-1 induces hypertension and vascular dysfunction in pregnant rats. FASEB J.22(Meeting abstracts), 969.3 (2008).
   Google Scholar
• Verlohren S, Niehoff M, Hering L et al. Uterine vascular function in a transgenic preeclampsia rat model. Hypertension51(2), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Dukes M, LaMarca BB, Cockrell K, Babcock SA, Granger JP. Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. Am. J. Hypertens.20(6), 686–691 (2007).
   PubMed Web of Science ®Google Scholar
• Schlager G. Genetic hypertension in mice. In: Handbook of Hypertension. Ganten D, DeJong W (Eds). Elsevier, London, UK (1994).
   Google Scholar
• Hoffmann DS, Weydert CJ, Lazartigues E et al. Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia. Hypertension51(4), 1058–1065 (2008).
   PubMedGoogle Scholar
• Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catechol-O-methyl transferase activity in the human term placenta. Am. J. Perinatol..5(2), 121–127 (1988).
   PubMed Web of Science ®Google Scholar
• Alexander BT, Llinas MT, Kruckeberg WC, Granger JP. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension43(4), 832–836 (2004).
   PubMed Web of Science ®Google Scholar
• Sholook MM, Gilbert JS, Sedeek MH, Huang M, Hester RL, Granger JP. Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. Am. J. Physiol. Heart Circ. Physiol.293(4), H2080–H2084 (2007).
   PubMed Web of Science ®Google Scholar
• Gutkowska J, Granger JP, LaMarca B et al. Cardiac hypertrophy and cardiac insulin responsive amino-peptidase (IRAP) in the reduced uterine perfusion (RUPP) model of preeclampsia. Hypertension46(5), 841–841 (2005).
   Google Scholar
• National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Consensus report. Am. J. Obstet. Gynecol.163, 1689–1712 (1990).
   Google Scholar
• Visser W, Wallenburg HC. Central hemodynamic observations in untreated preeclamptic patients. Hypertension17(6), 1072–1077 (1991).
   PubMed Web of Science ®Google Scholar
• Taylor RN, Roberts JM. Endothelial cell dysfunction. In: Chelsey’s Hypertensive Disorder’s of Pregnancy. Lindheimer M, Roberts JM, Cunningham FG (Eds). Appleton & Lange, CT, USA (2007).
   Google Scholar
• Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin. Reprod. Endocrinol.16(1), 17–31 (1998).
   PubMedGoogle Scholar
• Abid M, Schoots I, Spokes K, Wu S, Mawhinney C, Aird W. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IκB/NF-κB. J. Biol. Chem.279(42), 44030–44038 (2004).
   PubMedGoogle Scholar
• Abid M, Tsai J, Spokes K, Deshpande S, Irani K, Aird W. Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. FASEB J.15(13), 2548–2550 (2001).
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun.226(2), 324–328 (1996).
   PubMed Web of Science ®Google Scholar
• Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr. Res.57(5 Pt 2), 1R–7R (2005).
   Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metab.88(11), 5555–5563 (2003).
   PubMed Web of Science ®Google Scholar
• Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet. Gynecol.95(3), 353–357 (2000).
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ying Ma J et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension50(4), 686–692 (2007).
   PubMed Web of Science ®Google Scholar
• Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J. Clin. Endocrinol. Metab.92(7), 2672–2679 (2007).
   PubMed Web of Science ®Google Scholar
• Jerkic M, Rivas-Elena JV, Prieto M et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J.18(3), 609–611 (2004).
   PubMed Web of Science ®Google Scholar
• Li C, Issa R, Kumar P et al. CD105 prevents apoptosis in hypoxic endothelial cells. J. Cell Sci.116(13), 2677–2685 (2003).
   PubMed Web of Science ®Google Scholar
• Cudmore M, Ahmad S, Al-Ani B et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation115(13), 1789–1797 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh SW. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin. Reprod. Endocrinol.16(1), 93–104 (1998).
   PubMedGoogle Scholar
• Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am. J. Hypertens.4(8), 700–708 (1991).
   PubMed Web of Science ®Google Scholar
• Roberts JM, Balk JL, Bodnar LM, Belizan JM, Bergel E, Martinez A. Nutrient involvement in preeclampsia. J. Nutr.133(5), 1684S–1692S (2003).
   PubMed Web of Science ®Google Scholar
• Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; the ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N. Engl. J. Med.354(17), 1796–1806 (2006).
   PubMed Web of Science ®Google Scholar
• Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet367(9517), 1145–1154 (2006).
   PubMed Web of Science ®Google Scholar
• Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in shr with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension32(1), 59–64 (1998).
   PubMed Web of Science ®Google Scholar
• Sedeek MH, Sholook MM, Blazli C, Abram SR, Chandler DL, Granger JP. Tempol, but not vitamin E & C, decreases the blood pressure response to a chronic reduction in uterine perfusion pressure in pregnant rats. FASEB J.18(4), A740–A740 (2004).
   PubMedGoogle Scholar
• Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am. J. Physiol. Renal Physiol.288(4), F614–F625 (2005).
   PubMed Web of Science ®Google Scholar
• AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature407(6800), 94–98 (2000).
   PubMed Web of Science ®Google Scholar
• AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med.7(9), 1003–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Homuth V, Fischer T et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest.103(7), 945–952 (1999).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can. J. Physiol. Pharmacol.81(2), 79–83 (2003).
   PubMed Web of Science ®Google Scholar
• Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab.91(6), 2424–2427 (2006).
   PubMedGoogle Scholar
• Walther T, Wallukat G, Jank A et al. Angiotensin II Type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension46(6), 1275–1279 (2005).
   PubMed Web of Science ®Google Scholar
• Bobst SM, Day MC, Gilstrap LC 3rd, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens.18(3), 330–336 (2005).
   PubMed Web of Science ®Google Scholar
• Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J. Soc. Gynecol. Investig.10(2), 82–93 (2003).
   PubMedGoogle Scholar
• Zhou CC, Ahmad S, Mi T et al. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res.100(1), 88–95 (2006).
   PubMedGoogle Scholar
• Llinas M, Wallukat G, Dechend R et al. Agonistic autoantibodies to the At1 receptor in a rat model of preeclampsia induced by chronic reductions in uterine perfusion pressure (RUPP). Hypertension46(5), 884–884 (2005).
   Google Scholar
• Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Smith GD, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of preeclampsia: population based cohort study. BMJ335(7627), 978 (2007).
   PubMed Web of Science ®Google Scholar
• Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet. Gynecol.85(3), 353–356 (1995).
   PubMed Web of Science ®Google Scholar
• Lorentzen B, Drevon CA, Endresen MJ, Henriksen T. Fatty acid pattern of esterified and free fatty acids in sera of women with normal and preeclamptic pregnancy. Br. J. Obstet. Gynaecol.102(7), 530–537 (1995).
   PubMedGoogle Scholar
• Martinez Abundis E, Gonzalez Ortiz M, Quiones Galvan A, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with preeclampsia A controlled study. Am. J. Hypertens.9(6), 610–614 (1996).
   PubMed Web of Science ®Google Scholar
• Bartha J, Romero-Carmona R, Torrejon-Cardoso R, Comino-Delgado R. Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension. Am. J. Obstet. Gynecol.187(3), 735–740 (2002).
   PubMed Web of Science ®Google Scholar
• Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J. Clin. Endocrinol. Metab.88(6), 2393–2398 (2003).
   PubMed Web of Science ®Google Scholar
• Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J. Clin. Endocrinol. Metab.87(4), 1563–1568 (2002).
   PubMed Web of Science ®Google Scholar
• Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet. Gynecol.97(6), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Solomon CG, Graves SW, Greene MF, Seely EW. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension23(6), 717–721 (1994).
   PubMed Web of Science ®Google Scholar
• Joffe G, Esterlitz J, Levine R et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Am. J. Obstet. Gynecol.179(4), 1032–1037 (1998).
   PubMed Web of Science ®Google Scholar
• Thadhani R, Ecker JL, Mutter WP et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension43(5), 988–992 (2004).
   PubMed Web of Science ®Google Scholar
• Murai JT, Muzykanskiy E, Taylor RN. Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia. Metabolism46(8), 963–967 (1997).
   PubMed Web of Science ®Google Scholar
• Lorentzen B, Henriksen T. Plasma lipids and vascular dysfunction in preeclampsia. Semin. Reprod. Endocrinol.16(1), 33–39 (1998).
   PubMedGoogle Scholar
• Sattar N, Greer IA, Louden J et al. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. J. Clin. Endocrinol. Metab.82(8), 2483–2491 (1997).
   PubMed Web of Science ®Google Scholar
• Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension51(4), 939–944 (2008).
   PubMed Web of Science ®Google Scholar